EHP-101 是一种口服有效的特异性PPARγ和CB2受体双重激动剂，可抑制脯氨酰-羟化酶 (PHDs) 并激活HIF通路。它是一种半合成的多靶点大麻喹啉，可减弱脂肪生成并防止饮食诱导的肥胖，具有抗炎活性。

VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.

In HFD mice, VCE-004.8 (injection; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) [1].

1818428-24-8

C28H35NO3

433.58

VCE-004.8

DMSO:49 mg/mL (113.01 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years